Cargando…
A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953747/ https://www.ncbi.nlm.nih.gov/pubmed/36830943 http://dx.doi.org/10.3390/biomedicines11020407 |
_version_ | 1784893955003908096 |
---|---|
author | Osher, Esther Shalabna, Eiman Klausner, Joseph M. Greenman, Yona Stern, Naftali Shibolet, Oren Scapa, Erez Yakir, Oz Shor, Dana Ben-Ami Bar-Yishay, Iddo Shamai, Sivan Sofer, Yael Lubezky, Nir Goykhman, Yaacov Lahat, Guy Wolf, Ido Pelles, Sharon Aizic, Asaf Blachar, Arye Geva, Ravit |
author_facet | Osher, Esther Shalabna, Eiman Klausner, Joseph M. Greenman, Yona Stern, Naftali Shibolet, Oren Scapa, Erez Yakir, Oz Shor, Dana Ben-Ami Bar-Yishay, Iddo Shamai, Sivan Sofer, Yael Lubezky, Nir Goykhman, Yaacov Lahat, Guy Wolf, Ido Pelles, Sharon Aizic, Asaf Blachar, Arye Geva, Ravit |
author_sort | Osher, Esther |
collection | PubMed |
description | The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor. |
format | Online Article Text |
id | pubmed-9953747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99537472023-02-25 A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors Osher, Esther Shalabna, Eiman Klausner, Joseph M. Greenman, Yona Stern, Naftali Shibolet, Oren Scapa, Erez Yakir, Oz Shor, Dana Ben-Ami Bar-Yishay, Iddo Shamai, Sivan Sofer, Yael Lubezky, Nir Goykhman, Yaacov Lahat, Guy Wolf, Ido Pelles, Sharon Aizic, Asaf Blachar, Arye Geva, Ravit Biomedicines Article The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor. MDPI 2023-01-30 /pmc/articles/PMC9953747/ /pubmed/36830943 http://dx.doi.org/10.3390/biomedicines11020407 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Osher, Esther Shalabna, Eiman Klausner, Joseph M. Greenman, Yona Stern, Naftali Shibolet, Oren Scapa, Erez Yakir, Oz Shor, Dana Ben-Ami Bar-Yishay, Iddo Shamai, Sivan Sofer, Yael Lubezky, Nir Goykhman, Yaacov Lahat, Guy Wolf, Ido Pelles, Sharon Aizic, Asaf Blachar, Arye Geva, Ravit A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors |
title | A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors |
title_full | A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors |
title_fullStr | A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors |
title_full_unstemmed | A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors |
title_short | A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors |
title_sort | lymph node ratio model for prognosis of patients with pancreatic neuroendocrine tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953747/ https://www.ncbi.nlm.nih.gov/pubmed/36830943 http://dx.doi.org/10.3390/biomedicines11020407 |
work_keys_str_mv | AT osheresther alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shalabnaeiman alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT klausnerjosephm alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT greenmanyona alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT sternnaftali alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shiboletoren alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT scapaerez alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT yakiroz alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shordanabenami alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT baryishayiddo alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shamaisivan alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT soferyael alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT lubezkynir alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT goykhmanyaacov alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT lahatguy alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT wolfido alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT pellessharon alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT aizicasaf alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT blachararye alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT gevaravit alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT osheresther lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shalabnaeiman lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT klausnerjosephm lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT greenmanyona lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT sternnaftali lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shiboletoren lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT scapaerez lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT yakiroz lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shordanabenami lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT baryishayiddo lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT shamaisivan lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT soferyael lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT lubezkynir lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT goykhmanyaacov lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT lahatguy lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT wolfido lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT pellessharon lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT aizicasaf lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT blachararye lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors AT gevaravit lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors |